title: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
abstract: Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been associated with poor prognosis and provides strategic targets for novel therapy development. We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. Mer was also found to be expressed in 12 of 14 AML cell lines (86%). In contrast, normal bone marrow myeloid precursors expressed little to no Mer. Following AML cell line stimulation with Gas6, a Mer ligand, we observed activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6. To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1. Reduction of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation. Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67-87%, relative to control cell lines (P<0.01). NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, versus 32-36 days in Mer knockdown cell lines, P<0.0001). These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML.
authors.affiliation: Department of Pediatrics, Division of Hematology, Oncology, and Bone Marrow Transplantation, Aurora, CO, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Lee-Sherick
authors.forename: K M
authors.initials: KM
authors.lastname: Eisenman
authors.forename: S
authors.initials: S
authors.lastname: Sather
authors.forename: A
authors.initials: A
authors.lastname: McGranahan
authors.forename: P M
authors.initials: PM
authors.lastname: Armistead
authors.forename: C S
authors.initials: CS
authors.lastname: McGary
authors.forename: S A
authors.initials: SA
authors.lastname: Hunsucker
authors.forename: J
authors.initials: J
authors.lastname: Schlegel
authors.forename: H
authors.initials: H
authors.lastname: Martinson
authors.forename: C
authors.initials: C
authors.lastname: Cannon
authors.forename: A K
authors.initials: AK
authors.lastname: Keating
authors.forename: H S
authors.initials: HS
authors.lastname: Earp
authors.forename: X
authors.initials: X
authors.lastname: Liang
authors.forename: D
authors.initials: D
authors.lastname: DeRyckere
authors.forename: D K
authors.initials: DK
authors.lastname: Graham
mesh_terms: D017209:Apoptosis; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology; D010766:Phosphorylation; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000076202:c-Mer Tyrosine Kinase; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D017362:Cyclic AMP Response Element-Binding Protein; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; C097072:MERTK protein, human; D020794:Receptor Protein-Tyrosine Kinases; D000076202:c-Mer Tyrosine Kinase; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases